Prudent Precaution in Clinical Trials of Nanomedicines

Gary Marchant, Rachel A. Lindor

Research output: Contribution to journalArticle

7 Scopus citations

Abstract

Clinical trials of nanotechnology medical products present complex risk management challenges that involve many uncertainties and important risk-risk trade-offs. This paper inquires whether the precautionary principle can help to inform risk management approaches to nanomedicine clinical trials. It concludes that prudent precaution may be appropriate for ensuring the safety of such trials, but that the precautionary principle itself, especially in its more extreme forms, does not provide useful guidance for specific safety measures.

Original languageEnglish (US)
Pages (from-to)831-840
Number of pages10
JournalJournal of Law, Medicine and Ethics
Volume40
Issue number4
DOIs
StatePublished - Dec 2012

ASJC Scopus subject areas

  • Issues, ethics and legal aspects
  • Health Policy

Fingerprint Dive into the research topics of 'Prudent Precaution in Clinical Trials of Nanomedicines'. Together they form a unique fingerprint.

Cite this